CHAIR
:
SPEAKER
(S):
Luca De Nigro, MS (SPKAGY), Drugs Monitoring Register, Italian Medicines Agency (AIFA), Italy
Mitch Dekoven, MHA (SPKNON), Director - Health Economics and Outcomes Research, IMS Health, United States
Larry Liberti, MS,RPh,RAC (SPKNON), Executive Director, Centre For Innovation In Regulatory Science (CIRS), United States
Chih-Hwa Wallace Lin,
PhD (SPKAGY), Director, Division of Resource Development,
Center for Drug Evaluation, Taiwan
Wallace is Director for Resource Development of CDE. He was Advisor for MOEA, President of SyNovate, Associate Professor in National Chao-Tune Univ. He has worked in Carnegie-Mellon Univ. and in Medical School of Univ. of Pittsburgh after earned Ph.D. from Carnegie-Mellon Univ., in Pittsburgh, PA.
|
Carl DeMoor, PhD (SPKNON), Vice President Epidemiology NA, Mapi, United States
Description
A health technology assessment (HTA) is used to inform reimbursement decisions. However, because approaches are diverse, opportunities to share scientific information and best practices should be explored. This symposium aims to identify the process available to assess the value of medicines in real-world practice.